Advertisement
UK markets closed

  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     

  • HANG SENG

    18,313.86
    -165.51 (-0.90%)
     

  • CRUDE OIL

    78.69
    +0.31 (+0.40%)
     

  • GOLD FUTURES

    2,322.30
    -1.90 (-0.08%)
     

  • DOW

    38,959.02
    +74.76 (+0.19%)
     

  • Bitcoin GBP

    50,085.23
    -663.89 (-1.31%)
     

  • CMC Crypto 200

    1,327.83
    +33.15 (+2.56%)
     

  • NASDAQ Composite

    16,273.89
    -58.67 (-0.36%)
     

  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     
Money:

How to make a tax-free income

Tips for making money that won't be taxed

Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·3-min read

AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.

Continue reading